Company profile
Adagene Inc.
NASDAQ:ADAGBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ADG-106 | phase1_2 | — | 4 | completed, terminated |
| Firastotug | phase1 | — | 3 | completed, terminated |
| Muzastotug | phase1 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04501276 | phase1 | completed | 2020-09-23 | 2024-01-17 | Adagene Inc | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients |
| NCT05277402 | phase1 | completed | 2022-02-09 | 2022-08-01 | Adagene Inc | ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors |
| NCT05405595 | phase1_2 | recruiting | 2022-06-15 | 2026-10-31 | Adagene Inc | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors |
| NCT04645069 | phase1_2 | completed | 2021-03-15 | 2024-01-29 | Adagene Inc | ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors |
| NCT04775680 | phase1_2 | terminated | 2021-03-11 | 2023-02-09 | Adagene (Suzhou) Limited | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma |
FDA applications (0)
No records yet.